Matches in SemOpenAlex for { <https://semopenalex.org/work/W2418100960> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2418100960 endingPage "5" @default.
- W2418100960 startingPage "763" @default.
- W2418100960 abstract "In 2013 brimonidine tartrate gel 0.33% (Mirvaso Gel, Galderma Laboratories, LP, Fort Worth, TX) was approved by the US Food and Drug Administration for the treatment of facial erythema of rosacea. It is the first and only drug on the market to address the hallmark redness of this chronic, inflammatory disease. Commonly reported adverse events include erythema/flushing worse than at baseline, most often occurring with the first application. We report a unique case of facial erythema of rosacea that responded to brimonidine gel with effective blanching for two years until the patient developed a paradoxical erythema reaction. This is an adverse reaction physicians should be aware of with continued prescription of brimonidine gel for their rosacea patients.<br /><br /> <em>J Drugs Dermatol</em>. 2016;15(6):763-765." @default.
- W2418100960 created "2016-06-24" @default.
- W2418100960 creator A5064643606 @default.
- W2418100960 creator A5076559819 @default.
- W2418100960 date "2016-06-01" @default.
- W2418100960 modified "2023-09-23" @default.
- W2418100960 title "Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea." @default.
- W2418100960 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27272086" @default.
- W2418100960 hasPublicationYear "2016" @default.
- W2418100960 type Work @default.
- W2418100960 sameAs 2418100960 @default.
- W2418100960 citedByCount "5" @default.
- W2418100960 countsByYear W24181009602016 @default.
- W2418100960 countsByYear W24181009602017 @default.
- W2418100960 countsByYear W24181009602020 @default.
- W2418100960 crossrefType "journal-article" @default.
- W2418100960 hasAuthorship W2418100960A5064643606 @default.
- W2418100960 hasAuthorship W2418100960A5076559819 @default.
- W2418100960 hasConcept C141071460 @default.
- W2418100960 hasConcept C16005928 @default.
- W2418100960 hasConcept C197934379 @default.
- W2418100960 hasConcept C2777673923 @default.
- W2418100960 hasConcept C2778081122 @default.
- W2418100960 hasConcept C2778190193 @default.
- W2418100960 hasConcept C2779121184 @default.
- W2418100960 hasConcept C2781092963 @default.
- W2418100960 hasConcept C71924100 @default.
- W2418100960 hasConcept C98274493 @default.
- W2418100960 hasConceptScore W2418100960C141071460 @default.
- W2418100960 hasConceptScore W2418100960C16005928 @default.
- W2418100960 hasConceptScore W2418100960C197934379 @default.
- W2418100960 hasConceptScore W2418100960C2777673923 @default.
- W2418100960 hasConceptScore W2418100960C2778081122 @default.
- W2418100960 hasConceptScore W2418100960C2778190193 @default.
- W2418100960 hasConceptScore W2418100960C2779121184 @default.
- W2418100960 hasConceptScore W2418100960C2781092963 @default.
- W2418100960 hasConceptScore W2418100960C71924100 @default.
- W2418100960 hasConceptScore W2418100960C98274493 @default.
- W2418100960 hasIssue "6" @default.
- W2418100960 hasLocation W24181009601 @default.
- W2418100960 hasOpenAccess W2418100960 @default.
- W2418100960 hasPrimaryLocation W24181009601 @default.
- W2418100960 hasRelatedWork W140508764 @default.
- W2418100960 hasRelatedWork W2121670210 @default.
- W2418100960 hasRelatedWork W2386764277 @default.
- W2418100960 hasRelatedWork W2418100960 @default.
- W2418100960 hasRelatedWork W2525460195 @default.
- W2418100960 hasRelatedWork W3127866570 @default.
- W2418100960 hasRelatedWork W3203616849 @default.
- W2418100960 hasRelatedWork W4206474771 @default.
- W2418100960 hasRelatedWork W4210750705 @default.
- W2418100960 hasRelatedWork W4287103230 @default.
- W2418100960 hasVolume "15" @default.
- W2418100960 isParatext "false" @default.
- W2418100960 isRetracted "false" @default.
- W2418100960 magId "2418100960" @default.
- W2418100960 workType "article" @default.